PE20120653A1 - Forma cristalina iv de la agomelatina y la composicion que la comprende - Google Patents

Forma cristalina iv de la agomelatina y la composicion que la comprende

Info

Publication number
PE20120653A1
PE20120653A1 PE2011001513A PE2011001513A PE20120653A1 PE 20120653 A1 PE20120653 A1 PE 20120653A1 PE 2011001513 A PE2011001513 A PE 2011001513A PE 2011001513 A PE2011001513 A PE 2011001513A PE 20120653 A1 PE20120653 A1 PE 20120653A1
Authority
PE
Peru
Prior art keywords
agomelatin
crystalline form
composition
difraction
advantaged
Prior art date
Application number
PE2011001513A
Other languages
English (en)
Inventor
Hanbin Shan
Zhedong Yuan
Yu Huang
Xufeng Cao
Xiong Yu
Peng Zhang
Xudong Jiang
Hubo Wang
Xingdong Cheng
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41370233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120653(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20120653A1 publication Critical patent/PE20120653A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE AGOMELATINA CARACTERIZADA PORQUE EN EL DIAGRAMA DE DIFRACCION DE RAYOS X EN POLVO PRESENTA LOS SIGUIENTES ANGULOS DE DIFRACCION 2 THETA: 11,13º; 11,82º; 17,49º; 19,48º; 19,72º; 20,50º; 21,76º; 22,54º; 22,97º, 24,56º; 25,36º; 27,16º Y 31,93º. REFERIDA ADEMAS A UN PROCEDIMENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHA FORMA CRISTALINA PRESETNA UNA ALTA PUREZA, ESTABILIDAD Y BUENA REPRODUCIBILIDAD SIENDO VENTAJOSA PARA LA FORMULACION FARMACEUTICA
PE2011001513A 2009-03-10 2010-03-09 Forma cristalina iv de la agomelatina y la composicion que la comprende PE20120653A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910047329.2A CN101585779B (zh) 2009-03-10 2009-03-10 阿戈美拉汀的晶型vi及其制备方法和应用

Publications (1)

Publication Number Publication Date
PE20120653A1 true PE20120653A1 (es) 2012-06-14

Family

ID=41370233

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001513A PE20120653A1 (es) 2009-03-10 2010-03-09 Forma cristalina iv de la agomelatina y la composicion que la comprende

Country Status (27)

Country Link
US (1) US8614251B2 (es)
EP (1) EP2431355A4 (es)
JP (1) JP2012519715A (es)
KR (1) KR20110123266A (es)
CN (1) CN101585779B (es)
AP (1) AP3049A (es)
AU (1) AU2010223720B2 (es)
BR (1) BRPI1013249A2 (es)
CA (1) CA2754276A1 (es)
CL (1) CL2011002231A1 (es)
CO (1) CO6410293A2 (es)
CR (1) CR20110457A (es)
CU (1) CU20110162A7 (es)
EA (1) EA019127B1 (es)
EC (1) ECSP11011309A (es)
GE (1) GEP20146114B (es)
HN (1) HN2011002408A (es)
IL (1) IL214683A0 (es)
MA (1) MA33100B1 (es)
MX (1) MX2011009339A (es)
NI (1) NI201100167A (es)
PE (1) PE20120653A1 (es)
SG (2) SG173692A1 (es)
TN (1) TN2011000426A1 (es)
UA (1) UA100476C2 (es)
WO (1) WO2010102554A1 (es)
ZA (1) ZA201106049B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN102050756A (zh) * 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
CN102190595A (zh) 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102557979B (zh) * 2010-12-16 2014-11-26 北大方正集团有限公司 一种阿戈美拉汀的晶型、其制备方法、用途及药物组合物
WO2012093402A1 (en) * 2011-01-04 2012-07-12 Symed Labs Limited Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013082302A1 (en) 2011-11-30 2013-06-06 Ratiopharm Gmbh Agomelatine-urea complex and crystalline forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866334B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
EP2319827A1 (en) * 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine

Also Published As

Publication number Publication date
AP2011005914A0 (en) 2011-10-31
CN101585779B (zh) 2014-04-02
NI201100167A (es) 2012-01-11
JP2012519715A (ja) 2012-08-30
CN101585779A (zh) 2009-11-25
MX2011009339A (es) 2011-09-27
WO2010102554A1 (zh) 2010-09-16
CO6410293A2 (es) 2012-03-30
UA100476C2 (en) 2012-12-25
KR20110123266A (ko) 2011-11-14
EP2431355A4 (en) 2012-08-08
US8614251B2 (en) 2013-12-24
EA201101304A1 (ru) 2012-04-30
ZA201106049B (en) 2012-10-31
TN2011000426A1 (en) 2013-03-27
ECSP11011309A (es) 2011-10-31
GEP20146114B (en) 2014-07-10
AU2010223720B2 (en) 2012-05-03
CR20110457A (es) 2011-09-21
EP2431355A1 (en) 2012-03-21
AP3049A (en) 2014-11-30
SG173692A1 (en) 2011-09-29
CL2011002231A1 (es) 2012-02-03
US20120004313A1 (en) 2012-01-05
IL214683A0 (en) 2011-11-30
CA2754276A1 (en) 2010-09-16
SG177886A1 (en) 2012-02-28
AU2010223720A1 (en) 2011-09-08
CU20110162A7 (es) 2012-02-15
BRPI1013249A2 (pt) 2016-04-05
MA33100B1 (fr) 2012-03-01
HN2011002408A (es) 2014-06-23
EA019127B1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
PE20120653A1 (es) Forma cristalina iv de la agomelatina y la composicion que la comprende
PE20090912A1 (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
AR057714A1 (es) Nueva forma cristalina iv de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen
MX2015016543A (es) Derivados de biarilo como agonistas de gpr120.
CY1118036T1 (el) Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
AR076856A1 (es) Lenalidomida polimorfa y proceso para su preparacion
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
ECSP13012459A (es) Valsartan altamente cristalino
MX2009008124A (es) Cristal nuevo de piperacilina sodica.
MY166444A (en) Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same
CR20120655A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
UA116994C2 (uk) Стабілізована аморфна форма агомелатину, спосіб її одержання і фармацевтичні композиції, які її містять
AR089078A1 (es) Formas cristalinas de [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida de acido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxilico
MX2015011101A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.
JO3132B1 (ar) عملية تخليق مركبات 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one واستخدامها لإعداد ايفابرادين
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
TH120304A (th) รูปแบบที่เป็นผลึก vi แบบใหม่ของอะโกเมลาทีน, การเตรียม และการใช้ของสิ่งนี้

Legal Events

Date Code Title Description
FC Refusal